| First Author | Leibnitz RR | Year | 1995 |
| Journal | J Immunol | Volume | 155 |
| Issue | 4 | Pages | 1784-95 |
| PubMed ID | 7636234 | Mgi Jnum | J:28656 |
| Mgi Id | MGI:76177 | Doi | 10.4049/jimmunol.155.4.1784 |
| Citation | Leibnitz RR, et al. (1995) Protection from T helper cell-mediated graft-versus-host disease by the presence of an MHC class I alloantigen is associated with perturbation of MHC class II-restricted responses by class I-derived peptides. J Immunol 155(4):1784-95 |
| abstractText | Lethal graft-vs-host disease (GVHD) develops after transfer of CTL-depleted spleen and bone marrow cells from C57BL/6 (B6) mice to irradiated MHC class II disparate (B6xbm12)F1 recipients. Onset of lethal GVHD is significantly delayed in (bm1xbm12)F1 recipients of the same donor inoculum despite the additional MHC class I disparity (H-2Kbm1). To investigate the basis of this protective effect, hybridomas were generated from T cells activated in vivo during GVHD in both strain combinations. T cells from B6-->(B6xbm12)F1 mice generated a significantly higher frequency of B6.C-H-2bm12 (bm12)-specific T hybridomas (110/178, 62%) than T cells from B6-->(bm1xbm12)F1 mice (102/218, 47%). Some bm12-specific T hydridomas exhibited lesser responses to (bm1xbm12)F1 than to (B6xbm12)F1 APC. Moreover, bm1 peptides spanning a 14-amino acid region that includes the three amino acids that differ from H-2Kb were found to inhibit responses of some bm12-specific T hybridomas and to decrease significantly responses of splenic B6 CD4+ T cells to bm12 APC. Notably, the frequency of bm12-reactive hybridomas susceptible to inhibition by bm1 peptides generated from B6-->(B6xbm12)F1 mice was significantly greater than that generated from B6-->(bm1xbm12)F1 mice. Additional analysis using L cell transfectants indicated that hybridomas responding to the bm12 mutation at position 70 alone were rarely inhibited by bm1 peptides. The data indicate that expression of bm1-derived peptides can influence the frequency and specificity of alloreactive CD4+ T cells stimulated in vivo and thus may alter the course of GVHD. |
